Despite the potential benefits, targeting cyclins in cancer therapy comes with challenges. One major issue is the redundancy and compensatory mechanisms among different cyclins and CDKs, which can undermine the effectiveness of inhibitors. Additionally, the side effects of CDK inhibitors, such as myelosuppression and gastrointestinal toxicity, need to be carefully managed.
